Porcine factor VIII provides clinical benefit to patients with high levels of inhibitors to human and porcine factor VIII

Haemophilia

Volumn 6, Issue 5, 2000, Pages 482-486

  Gribble, J ^a   Garvey, M B ^b  

^a St Michael's Hospital ^*  (United States)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Factor VIII inhibitor; FEIBA; Haemophilia; Platelet activation; Porcine factor VIII

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 INHIBITOR; IMMUNOSUPPRESSIVE AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ANTIBODY TITER; BLEEDING; CASE REPORT; CHILD; CLINICAL FEATURE; CONTINUOUS INFUSION; CROSS REACTION; DOSE RESPONSE; DRUG INFUSION; DRUG MEGADOSE; HEMOPHILIA; HEMOSTASIS; HUMAN; IMMUNOADSORPTION; IMMUNOLOGICAL TOLERANCE; MALE; MORBIDITY; MORTALITY; PATIENT CARE; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW;

ANIMAL; ANTIBODIES, HETEROPHILE; CASE REPORT; CHILD, PRESCHOOL; FACTOR VIII; HEMOPHILIA A; HEMORRHAGE; HUMAN; INFANT; ISOANTIBODIES; MALE; SWINE; THROMBOCYTOPENIA;

EID: 0033832861     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2000.00403.x     Document Type: Review

References (19)

1. Safety and immunogenicity of recombinant Factor VIII (RECOMBINATE(TM) in previously untreated patients (PUPs)
2. Continuous infusion of porcine Factor VIII for the treatment of patients with Factor VIII inhibitors
3. The in vitro stability of porcine Factor VIII (PFVIII) HYATE. C) and the efficacy of continuous infusion (CI) PFVIII in the treatment of patients with FVIII antibodies
4. The use of porcine Factor VIII concentrate (HYATE:C) in the treatment of patients with inhibitor antibodies to Factor VIII
5. Efficacy of porcine Factor VIII in the management of haemophiliacs with inhibitors
6. Use of porcine Factor VIII for surgical procedures in hemophilia A patients with inhibitors
7. Porcine Factor VIII therapy in patients with congenital hemophilia and inhibitors: Efficacy, patient selection, and side effects
8. Use of porcine Factor VIII in the management of seventeen patients with Factor VIII antibodies
9. Clinical experience with polyelectrolytes-fractionated porcine Factor VIII concentrate in the treatment of hemophiliacs with antibodies to Factor VIII
10. Porcine Factor VIII therapy in patients with Factor VIII inhibitors.
11. The use of porcine factor VIII in France
12. Induction of immune tolerance in patients with hemophilia and antibodies to Factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and Factor VIII
13. The relevance of Factor VIII inactivation characteristics in the treatment of patients with antibodies directed against Factor VIII
14. Molecular characterization of commercial porcine Factor VIII concentrate
15. Structural basis for the decreased procoagulant activity of human Factor VIII compared to the porcine homolog
16. Coagulant properties of hybrid human/porcine Factor VIII molecules
17. Porcine von Willebrand Factor binding to human platelet GP1b induces transmembrane calcium influx
18. Platelet activation induced by porcine Factor VIII (HYATE:C)